Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Epoetin Biosimilar Serve As Non-Medical Switching Case Study?

Executive Summary

Analysts expect potential broad uptake of biosimilars in chronic kidney disease treated at dialysis centers, which could lead to patients being switched off Amgen's Epogen.

Advertisement

Related Content

Biosimilars: US FDA Education Campaign Is Non-Committal On Non-Medical Switching
Biosimilar Advisory Committees Getting Smoother, Even As Worries Stay The Same
Hospira's Epogen Biosimilar Appears Poised For Quick Advisory Cmte. OK
Biosimilar Prescribing Decisions May Depend Upon Disease State
UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
FDA Biosimilar Education Campaign Will Need To Be Targeted

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098957

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel